(Q54011326)

23 May 2018

title

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib. (English)

1 reference

23 May 2018

E Dean

5

0 references

author name string

J Mateo

1

1 reference

23 May 2018

V Moreno

2

1 reference

23 May 2018

A Gupta

3

1 reference

23 May 2018

S B Kaye

4

1 reference

23 May 2018

M R Middleton

6

1 reference

23 May 2018

M Friedlander

7

1 reference

23 May 2018

C Gourley

8

1 reference

23 May 2018

R Plummer

9

1 reference

23 May 2018

G Rustin

10

1 reference

23 May 2018

C Sessa

11

1 reference

23 May 2018

K Leunen

12

1 reference

23 May 2018

J Ledermann

13

1 reference

23 May 2018

H Swaisland

14

1 reference

23 May 2018

A Fielding

15

1 reference

23 May 2018

W Bannister

16

1 reference

23 May 2018

S Nicum

17

1 reference

23 May 2018

L R Molife

18

1 reference

23 May 2018

publication date

1 June 2016

1 reference

23 May 2018

published in

Targeted oncology

1 reference

23 May 2018

volume

11

1 reference

23 May 2018

issue

3

1 reference

23 May 2018

page(s)

401-415

1 reference

23 May 2018

https://scigraph.springernature.com/pub.10.1007/s11523-016-0435-8

exact match

0 references

cites work

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0435-8

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0435-8

BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0435-8

Integrated genomic analyses of ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0435-8

Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0435-8

Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0435-8

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0435-8

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0435-8

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0435-8

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0435-8

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0435-8

Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0435-8

Predictive biomarkers for cancer therapy with PARP inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0435-8

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0435-8

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0435-8

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0435-8

Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0435-8

Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0435-8

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0435-8

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0435-8

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27169564

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27169564

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

1 reference

https://pubmed.ncbi.nlm.nih.gov/27169564

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11523-016-0435-8

1 reference

23 May 2018

1 reference

23 May 2018